The Law Firm of Weiss & Lurie Announces Investigation of Allos Therapeutics, Inc.

Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Allos Therapeutics, Inc. (Nasdaq: ALTH) arising from its proposed acquisition by AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) in an all-stock transaction valued at approximately $686 million. Under the terms of the transaction, Allos shareholders will receive a fixed ratio of 0.1282 shares of AMAG common stock for each share of Allos common stock. The proposed deal values Allos stock at only $2.09 per share using AMAG’s Wednesday’s closing price of $16.31.

Weiss & Lurie is investigating whether the Company’s Board acted in the best interests of shareholders in approving the transaction and whether the Board properly sought to maximize shareholder value by conducting an adequate and fair sales process. Multiple analysts have set target prices for Allos stock well above the price agreed to by Allos directors, with a high target price of $8.00.

If you own Allos shares and would like more information about your rights as a shareholder or additional information concerning our investigation, please contact Michael A. Rogovin either by email at info@weisslurie.com or by telephone at (888) 593-4771.

Weiss & Lurie has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded institutions and individuals and obtained important corporate governance in these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (such as insider trading, waste of corporate assets, accounting fraud, or issuing materially misleading press releases or SEC filings), consumer fraud (such as false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at info@weisslurie.com or fill out the form on our website, http://www.weisslurie.com/contact/report_fraud/.

Attorney Advertising. Past results do not guarantee a similar outcome.

Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From May 2024 to Jun 2024